Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal

STOCKHOLM, March 20, 2023 /PRNewswire/ — BioArctic AB’s (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ) protofibril[1] antibody lecanemab (generic name, U.S….